We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...

We recently published a list of 10 Stocks with Potential to Explode in 2025. In this article, we are going to take a look at ...

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. In terms of liquidity ...

The company has already sent the FDA an application for a seasonal flu vaccine, but the agency will probably wait for upcoming data from an ongoing phase 3 study before it issues a decision. In ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent ... while investors focused on data pointing to a cooling U.S. economy. Novavax sees royalties, reduced expenses ...

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

After hours: March 27 at 7:58:56 PM EDT Loading Chart for MRNA ...